FASN and hepatocellular carcinoma: Inspired by our present findings showing a lower proliferation and higher apotpotic rates in tumors genetically deprived of FASN, we assessed the levels of some of the identified FASN targets [30,31] in normal wild-type livers as well as in c-Myc/MCL1/pCMV and c-Myc/MCL1/Cre mouse HCC lesions (Figure 12).